Related Experiment Video
Updated: Apr 14, 2026
Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
Published on: June 29, 2022
Targeted senotherapy improves electrographic and behavioral outcomes in a mouse model of temporal lobe epilepsy
David J McFall1,2, Abbas I Hussain2, Michelle Cho2
1Interdisciplinary Program in Neuroscience, Georgetown University, Washington, DC, USA.
Objective:
Current pharmacotherapy for temporal lobe epilepsy (TLE) is limited to symptomatic treatment and leaves approximately one third of patients with inadequate seizure control. Discovering disease-modifying targets is an unmet clinical need. We have previously identified senescent cells (SCs) as one such target. Many drugs that eliminate SCs (senolytics) interfere with apoptotic resistance proteins, potentially resulting in broad cytotoxicity and numerous side effects. Newer, more targeted therapies, like selective senescence killing compound 1 (SSK1), a gemcitabine prodrug that is selectively activated in SCs, offer the possibility to reduce off-target effects, but SSK1 has yet to be investigated in any preclinical epilepsy model.
Methods:
We used pilocarpine to induce status epilepticus (SE) in 3- to 4-month-old mice. Immediately following SE, mice were randomly assigned to receive either SSK1 treatment or vehicle for the remainder of the study. We assessed behavioral performance on memory tasks, seizure burden by EEG, and histological markers of SCs.
Results:
SE robustly increased hippocampal and thalamic expression of SC marker p16 by over 100% compared to saline controls. SSK1 treatment reduced p16+ cells by ~45%, without any apparent neurotoxicity. In addition, SSK1 treatment normalized spatial memory impairments and reduced spontaneous seizure burden, completely protecting a majority (60%) of animals from seizures. SC burden in the hippocampus, but not the thalamus, correlated with seizure burden in vehicle-treated animals.
Significance:
These findings lend further credence to the viability of targeting SCs to treat TLE. As with other genetic and pharmacologic SC ablation strategies, SSK1 produced a similar reduction in p16+ cells and normalization of spatial memory. SSK1, however, displays a stronger protective effect against seizures. In short, SSK1 is a compelling, translationally viable option for senolysis in TLE.
Insights
Selective senescence killing compound 1 (SSK1) effectively targets senescent cells (SCs) to reduce seizures and improve memory in a temporal lobe epilepsy (TLE) mouse model. This novel senolytic therapy shows promise for treating TLE by addressing disease modification.
Area of Science:
- Neuroscience
- Pharmacology
- Cell Biology
Background:
- Current temporal lobe epilepsy (TLE) treatments offer limited efficacy for a significant patient subset.
- Senescent cells (SCs) are identified as a potential disease-modifying target for TLE.
- Existing senolytic drugs may cause cytotoxicity; novel targeted therapies are needed.
Purpose of the Study:
- To investigate the efficacy of selective senescence killing compound 1 (SSK1), a targeted senolytic, in a preclinical model of TLE.
- To assess SSK1's impact on senescent cell burden, seizure activity, and cognitive function.
Main Methods:
- Status epilepticus (SE) was induced using pilocarpine in mice.
- Mice received SSK1 or vehicle treatment post-SE.
- EEG monitored seizure burden, memory tasks assessed cognitive performance, and p16 expression identified SCs.
Main Results:
- SE increased SC marker p16 expression in the hippocampus and thalamus.
- SSK1 treatment significantly reduced p16+ cells without neurotoxicity.
- SSK1 normalized spatial memory deficits and reduced spontaneous seizure frequency, protecting 60% of animals.
Conclusions:
- Targeting senescent cells (SCs) is a viable strategy for TLE treatment.
- SSK1 demonstrates significant neuroprotective and anti-seizure effects in a TLE model.
- SSK1 represents a promising, translationally viable senolytic therapeutic for TLE.
More Related Videos
09:29Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
Published on: August 17, 2021
10:08The Pilocarpine Model of Temporal Lobe Epilepsy and EEG Monitoring Using Radiotelemetry System in Mice
Published on: February 27, 2018